Publications by authors named "A Didierlaurent"
Article Synopsis
- Chronic urticaria (CU) has been reported in some individuals after receiving the Moderna mRNA-1273 vaccine, prompting this study to analyze its onset related to COVID-19 vaccination, SARS-CoV-2 infection, and atopy factors.
- A study involving 50 individuals with CU and 135 without CU assessed the immunological responses and the presence of anti-vaccine IgE through surveys and blood tests conducted in 2022 and 2023.
- Results indicated that post-vaccination CU typically appears about 10 days after the Spikevax booster, especially affecting middle-aged women, with 53% of cases still active in 2023; however, some patients tolerated additional doses without worsening their symptoms,
Article Synopsis
- Next-generation COVID-19 vaccines aim to improve coverage against existing and future variants while extending protection duration; the Prime-2-CoV_Beta vaccine uses an ORF virus platform to present multiple antigens.
- A phase 1 trial (ORFEUS study) tested the safety and immune response of Prime-2-CoV_Beta in participants aged 18-55 and 65-85 who previously received mRNA vaccines, with doses administered on day 1 and day 29.
- Results showed that Prime-2-CoV_Beta is safe, well tolerated, and generates strong immune responses, especially in younger participants, suggesting the ORFV platform's potential for future vaccine development.
Vaccine adjuvants are thought to work by stimulating innate immunity in the draining lymph node (LN), although this has not been proven in humans. To bridge the data obtained in animals to humans, we have developed an in situ human LN explant model to investigate how adjuvants initiate immunity. Slices of explanted LNs were exposed to vaccine adjuvants and revealed responses that were not detectable in LN cell suspensions.
View Article and Find Full Text PDFThe adjuvant AS01 plays a key role in the immunogenicity of several approved human vaccines with demonstrated high efficacy. Its adjuvant effect relies on activation of the innate immune system. However, specific effects of AS01-adjuvanted vaccines on innate cell function and epigenetic remodeling, as described for Bacille Calmette-Guérin (BCG) and influenza vaccines, are still unknown.
View Article and Find Full Text PDFBackground: Treatment with anti-CD20 antibodies (rituximab) is used in both adults and children to treat various autoimmune and oncological diseases. Rituximab depletes B CD20+ cells and, thereby, antibody response to vaccines. This study aimed to examine the antibody response to mRNA-based COVID-19 vaccines in children aged 5-18 years undergoing rituximab treatment compared to healthy matched children.
View Article and Find Full Text PDF